All relevant data are within the manuscript and its Supporting Information files. The protocol is held in a data repository (DOI: [10.26182/5eec2f4221726](https://doi.org/10.26182/5eec2f4221726)).

Introduction {#sec004}
============

Coronary artery disease (CAD) is an important cause of morbidity and mortality globally \[[@pone.0236598.ref001]\]. Preventative strategies can be effective when targeted at individuals at increased risk of CAD. At present, we rely on cardiovascular risk prediction algorithms to identify persons at high risk of CAD. These probabilistic algorithms often underestimate the risk of CAD in women \[[@pone.0236598.ref002]\] leading to under prescription of preventative therapies and lifestyle changes. Female-specific strategies may more accurately identify women at risk of CAD.

Coronary calcification is strongly associated with an increased risk of CAD in people without prior CAD events \[[@pone.0236598.ref003]\]. Non-coronary arterial calcification, such as in the peripheral arteries, is also associated with an increased risk of CAD \[[@pone.0236598.ref004]\]. It is, therefore, conceivable that detection of non-coronary artery calcification may be useful to screen for quiescent CAD provided that the cost and logistics of screening can be justified.

Mammography is widely used to screen for breast cancer in women aged 40 years and older. Breast arterial calcification (BAC) is a frequent incidental finding on screening mammography but is not routinely reported. It is a form of medial arterial calcification \[[@pone.0236598.ref005]\] which occur in the absence of atherosclerosis and inflammation \[[@pone.0236598.ref005]--[@pone.0236598.ref007]\]. Therefore, it has been assumed that BAC or medial arterial calcification are not involved in CAD. Yet, two meta analyses \[[@pone.0236598.ref008],[@pone.0236598.ref009]\] and a systematic review \[[@pone.0236598.ref010]\] have suggested that there may be an association between BAC and CAD and cardiovascular events. This has garnered interest among both clinicians and women who undergo mammography in whether BAC could be used to assess cardiovascular risk in women \[[@pone.0236598.ref011]\] and in response, there has been a number of publications since these studies have been published that have examined the association between BAC and CAD. The primary aim of this systematic review is to assess the current evidence for the association between BAC and the risk of CAD and whether the association is consistent across different modalities for assessing CAD. The secondary aim of this review is to ascertain if BAC is associated with major cardiovascular risk factors (hypertension, diabetes mellitus, hypercholesterolemia and smoking). We also assessed the effects of the method of quantification of BAC severity on the association with CAD.

Methods {#sec005}
=======

This review was registered with PROSPERO (CRD42020141644) and was conducted in accordance with the Preferred Reported Items for Systematic Review and Meta-Analyses (PRISMA) statement. The protocol has also been registered (DOI: [10.26182/5eec2f4221726](https://doi.org/10.26182/5eec2f4221726)).

Data sources and searches {#sec006}
-------------------------

A literature search for relevant articles published up to 2 August 2019 was conducted and updated on 18 February 2020 using MEDLINE and EMBASE databases. To provide an updated systematic review of the association of BAC and CAD and its risk factors, a similar search strategy from the previous systematic review \[[@pone.0236598.ref010]\] was used. This included the following keywords and/or Medical Subject Heading terms: "Breast\" OR "mamma" OR "mammary" OR "mammograph\*" OR "intramammary" AND "vessel" OR "vessels" OR "artery" OR "arterial" OR "arteries" OR "vascular" AND "calcif\*" OR "scleros\*" OR "calcinos\*" OR "calcium ([S1 Table](#pone.0236598.s001){ref-type="supplementary-material"}). Additional papers were identified from the reference lists of papers identified in the search.

Study selection {#sec007}
---------------

Any English language study that examined the associations of BAC and CAD and its risk factors (diabetes mellitus, hypertension, hypercholesterolemia and smoking) were included. To examine CAD specifically, CAD was defined as any cardiovascular events as reported by participants or obtained by medical records (previous myocardial infarction, angina, previous abnormal coronary angiography or functional test, revascularisation) or presence of CAD on coronary angiography (CAG) or presence of perfusion defect on myocardial perfusion scan (MPS) or the presence of atherosclerosis on computed-tomography coronary angiography (CTCA) or CT chest or coronary calcium scores (CCS). When there were studies using the same cohort of participants, only the study of better quality and design (i.e. cohort studies over cross sectional studies) was selected for analysis. Case reports, case series and conference proceedings were excluded as they do not contain sufficient information and were deemed to be at high risk of bias.

All titles and abstracts were screened for inclusion by a single reviewer. Queries regarding the eligibility of a particular study were independently evaluated by a senior reviewer (CS or EW). Any additional references identified from full text review that potentially met the study eligibility criteria underwent the same process as described above.

Data extraction and quality assessment {#sec008}
--------------------------------------

Extracted data included: information of the publication (Author, Journal, Year, Title), study design, characteristics of the participants (sample size, average age or age range), prevalence of BAC, description of method of quantifying BAC, description of method of identifying or quantifying CAD (self-report, medical records, CCS, CTCA, CAG or MPS), study's conclusions on the associations of BAC with CAD and its risk factors, record of whether the study accounted for confounders in their final analysis and description of weaknesses of the study. Where available, dichotomous data required to calculate the ORs for the associations of BAC with CAD and its risk factors were also tabulated. When there were multiple information regarding cardiovascular events, objective measures such as abnormal coronary angiography over a history of myocardial infarction was extracted.

Study quality was assessed by a single reviewer (SCL) and quality scores were independently assessed by a second reviewer (CS or EW) where there was uncertainty. The Newcastle Ottawa Scale (NOS) for case control and cohort studies \[[@pone.0236598.ref012]\] was used to assess the quality of case control and cohort studies, respectively. The NOS uses a nine star point system to evaluate the studies' selection criteria of the study population (four points maximum), method of control for confounders (two points maximum) and the appropriateness of measurement of outcome (three points maximum). To be considered moderate in quality, a study needs to achieve at least two points in the selection criteria, at least one point for controlling for confounders and at least two points in the outcome criteria. A good quality study would need a score of at least three points in the selection criteria, one point for controlling for confounders and at least two points in the outcome criteria. As there is currently no validated measurement tool for assessing the quality of cross-sectional studies, a modified version of the NOS was created to assess the quality of cross sectional studies ([S1 Fig](#pone.0236598.s005){ref-type="supplementary-material"}). This adapted scale similarly assesses the quality of the studies except a ten point scale system is used (five points for selection criteria; two points for controlling for confounders; three points for outcome criteria). A score of five to six was considered as moderate and a score of seven or more as good in quality.

Data synthesis and analysis {#sec009}
---------------------------

A random effects model was used for the meta-analysis of BAC and CAD and its risk factors, assuming heterogeneity across different studies. Heterogeneity was tested using the chi-square Cochran's Q test and I^2^ statistic. Further analysis of the associations between BAC and CAD was conducted by stratifying the studies based on modality used to determine CAD (questionnaire/medical records; CT (CCS, CT chest, CTCA); CAG/MPS) and by method of quantification of BAC (absent/present vs semi-quantitative methods). The association of BAC severity and the presence of CAD was also evaluated. As age is well known determinant of BAC prevalence, a meta-regression analysis was performed with the log odds of the association of BAC with CAD as the dependent variable (y) and the mean difference of age as an independent variable (x). The mean difference of age was calculated by subtracting the average mean age of all the studies included in the analysis from the mean age of each study. Where a mean age was not provided, the median value was used. Study quality was also investigated as an independent variable (x). Sensitivity analyses excluding studies with less than 100 participants was performed to assess the impact on heterogeneity. The risk of publication bias in studies that have assessed the association of BAC with CAD was evaluated using a funnel plot. For the examination of the associations of BAC and cardiovascular risk factors, subgroup analyses involving only good quality studies were performed for each variable to assess if study quality was a determinant of the heterogeneity between studies. A p-value of less than 0.05 was considered to be statistically significant. Analyses were performed using R studio (version 3.5.2) and the 'meta' and 'metafor' packages.

Results {#sec010}
=======

A total of 3,724 scientific publications were identified through database searching. After removal of duplicates and hand searching references of these articles, there were 2,930 unique publications of which 205 were original research articles that were suitable to be retrieved for full text assessment for eligibility. Of these, only 58 articles were deemed relevant and one additional study was identified on an updated searched which resulted in a total of 59 studies that were included in our final analysis ([Fig 1](#pone.0236598.g001){ref-type="fig"}). These were all cross-sectional observational studies apart from five that were longitudinal studies. A total of 26 studies were considered good in quality. The characteristics of these 59 studies are provided in [Table 1](#pone.0236598.t001){ref-type="table"} and the critical appraisals are provided in [S2](#pone.0236598.s002){ref-type="supplementary-material"}--[S4](#pone.0236598.s004){ref-type="supplementary-material"} Tables.

![Search strategy flowchart.](pone.0236598.g001){#pone.0236598.g001}

10.1371/journal.pone.0236598.t001

###### Characteristics of studies included in the meta-analysis.

![](pone.0236598.t001){#pone.0236598.t001g}

  Author                                       Year   Design                   Follow up period   N        Age (mean)                  BAC prevalence
  -------------------------------------------- ------ ------------------------ ------------------ -------- --------------------------- -----------------------------------------------
  Baum \[[@pone.0236598.ref013]\]              1980   CS                       \-                 319      ?                           11.6%
  Sickles \[[@pone.0236598.ref014]\]           1985   CS                       \-                 5000     ?                           9.6%
  Van Noord \[[@pone.0236598.ref015]\]         1996   CS                                          12,239   (57.7)                      9.0%
  Crystal \[[@pone.0236598.ref016]\]           2000   CS                       \-                 865      (65/54 BAC+/-)              17.6%
  Cetin \[[@pone.0236598.ref017]\]             2004   CS                       \-                 2400     32--75                      9.1%
  Iribarren \[[@pone.0236598.ref018]\]         2004   Cohort                   25 years           12,761   40--79                      3.0%
  Maas (I) \[[@pone.0236598.ref019]\]          2006   CS                       \-                 1699     49--70                      11.4%
  Taşkin \[[@pone.0236598.ref020]\]            2006   CC (BAC)                 \-                 985      \>40                        7.9%
  Dale (II) \[[@pone.0236598.ref021]\]         2008   CS                       \-                 1000     23--93                      16.0%
  Pidal \[[@pone.0236598.ref022]\]             2009   CC (BAC)                 \-                 136      (57/55 BAC+/-)              8.4%
  Akinola \[[@pone.0236598.ref023]\]           2011   CS                       \-                 54       (60/51 BAC+/-)              20.0%
  Sedighi \[[@pone.0236598.ref024]\]           2011   CC (BAC)                 \-                 204      (60.6)                      14.7%
  Schnatz \[[@pone.0236598.ref025]\]           2011   Cohort                   5 years            1,454    (56.3)                      14.2%
  Friedlander \[[@pone.0236598.ref026]\]       2012   CS                       \-                 40       (62.2)                      22.5%
  Zafar \[[@pone.0236598.ref027]\]             2013   CS                       \-                 200      (56/44 BAC+/-)              13.5%
  Kosovic \[[@pone.0236598.ref028]\]           2015   CC (BAC)                 \-                 300      (62.0)                      ?
  Hanafi \[[@pone.0236598.ref029]\]            2018   CC (CAD)                 \-                 60       (53/51 CAD+/-)              60.0%
  Soylu \[[@pone.0236598.ref030]\]             2018   CS                       \-                 404      \>40                        30.4%
  Bae \[[@pone.0236598.ref031]\]               2013   CC (BAC)                 \-                 201      (58.9)                      \-
  Matsumura \[[@pone.0236598.ref032]\]         2013   CC (BAC)                 \-                 202      (60/58 BAC+/-)              \-
  Yagtu \[[@pone.0236598.ref033]\]             2015   CC (BAC)                 \-                 80       39--86                      ?
  Margolies \[[@pone.0236598.ref034]\]         2016   CS                       \-                 292      (61.5)                      42.5%
  Moshyedi \[[@pone.0236598.ref035]\]          1995   CS                       \-                 182      39--92                      24.2%
  Henkin \[[@pone.0236598.ref036]\]            2003   CC (CAD)                 \-                 319      (61.8)                      41.1%
  Fiuza Ferreira \[[@pone.0236598.ref037]\]    2007   CS                       \-                 131      (61.1)                      39.7%
  Topal \[[@pone.0236598.ref038]\]             2007   CS                       \-                 123      (64/52 BAC+/-)              39.8%
  Oliveira \[[@pone.0236598.ref039]\]          2009   CC (CAD)                 \-                 80       (64.65)                     \-
  Penugonda \[[@pone.0236598.ref040]\]         2010   CS                       \-                 94       (66.7)                      60.6%
  Zgheib \[[@pone.0236598.ref041]\]            2010   CC (CAD)                 \-                 172      (64.3)                      33.1%
  Hekimoğlu \[[@pone.0236598.ref042]\]         2012   CS                       \-                 55       \(63\)                      41.8%
  Moradi \[[@pone.0236598.ref043]\]            2014   CS                       \-                 150      (68/54 BAC+/-)              23.3%
  Karm \[[@pone.0236598.ref044]\]              2015   CS                       \-                 198      \(65\)                      41.4%
  Chadashvilli \[[@pone.0236598.ref045]\]      2016   CS                       \-                 145      (56/61 BAC+/-)              25.5%
  Fathala (I) \[[@pone.0236598.ref046]\]       2017   CS                       \-                 435      \(58\)                      59%
  Kelly \[[@pone.0236598.ref047]\]             2018   Cohort                   20.6 months        104      (58.93)                     14%
  Ružičić \[[@pone.0236598.ref048]\]           2018   CS                       \-                 102      \(62\)                      63.7%
  McLenachan \[[@pone.0236598.ref049]\]        2019   CS                       \-                 405      \(58\)                      23.0%
  ***Population*: *post-menopausal***                                                                                                  
  Kataoka \[[@pone.0236598.ref050]\]           2006   CS                       \-                 1590     (63.2)                      16.0%
  Yildiz (III) \[[@pone.0236598.ref051]\]      2008   CC (BAC)                 \-                 54       (62.7)                      10.2%
  Ferreira \[[@pone.0236598.ref052]\]          2009   CS                       \-                 307      (55.3)                      8.5%
  Nasser \[[@pone.0236598.ref053]\]            2014   CS                       \-                 211      (62.1)                      18.0%
  Atci \[[@pone.0236598.ref054]\]              2015   CC (BAC)                 \-                 567      (65/55 BAC+/-)              31.6%
  Pecchi \[[@pone.0236598.ref055]\]            2003   CS                       \-                 74       \<65                        59.5%
  Yildiz (II) \[[@pone.0236598.ref056]\]       2014   CS                       \-                 310      (55.9)                      33.9%
  Parikh \[[@pone.0236598.ref057]\]            2019   CS                       \-                 3507     60--79                      27.9%
  Maas (II) \[[@pone.0236598.ref058]\]         2004   CS                       \-                 600      (70/67 BAC+/-)              23.0%
  ***Population*: *diabetes***                                                                                                         
  Schmitt \[[@pone.0236598.ref059]\]           1985   CC (DM)                  \-                 450      35--74                      45.1%
  Dale (I) \[[@pone.0236598.ref060]\]          2010   CC (DM)                  \-                 1609     24--93                      36.5%
  Sankaran \[[@pone.0236598.ref061]\]          2019   CC (BAC)                 \-                 100      (59/51 BAC+/-)              ?
  ***Population*: *chronic kidney disease***                                                                                           
  Abou Hassan \[[@pone.0236598.ref062]\]       2015   Cohort                   3.3 years          202      (61/ 54 BAC+/-)             58.4%
  Voyvoda \[[@pone.0236598.ref063]\]           2019   CS                       \-                 55       (54.8)                      14.5%
  ***Other***                                                                                                                          
  Wada \[[@pone.0236598.ref064]\]              2012   CC (breast cancer)       \-                 3771     (56/58 breast cancer +/-)   9.9% (breast cancer) 14.3% (no breast cancer)
  Soran \[[@pone.0236598.ref065]\]             2014   Cohort (breast cancer)   7.5 years          602      (62/54 BAC+/-)              26.7%
  Mostafavi \[[@pone.0236598.ref066]\]         2015   CS                       \-                 100      (65.3)                      12.0%
  Yildiz (IV) \[[@pone.0236598.ref067]\]       2016   CC (premenopausal)       \-                 166      (45/45 BAC+/-)              ?
  Ronzani \[[@pone.0236598.ref068]\]           2017   CS                       \-                 312      (55.9)                      23.0%
  Fathala (II) \[[@pone.0236598.ref069]\]      2018   CS                       \-                 307      (54/59 BAC+/-)              46.3%
  Yildiz (I) \[[@pone.0236598.ref070]\]        2018   CC (BAC)                 \-                 132      \(54\)                      \-
  Sarrafzadegann \[[@pone.0236598.ref071]\]    2009   CS (premenopausal)       \-                 84       \<55                        7.1%

Abbreviations---CC: case control (variable used to separate cases and controls); BAC: breast arterial calcification; CS: cross sectional; DM: diabetes mellitus; CAD: coronary artery disease; CKD: chronic kidney disease; Green shading indicates studies that only included participants with no known history of cardiovascular disease; Orange shading indicates studies that only included participants with known history of cardiovascular disease.

Studies evaluating BAC and CAD {#sec011}
------------------------------

Of the 59 studies, 38 examined the association between BAC and CAD. Out of these, only 31 studies (n = 35,583) had data available to calculate the OR of the association of BAC and CAD. Only three of these studies were longitudinal and the rest were cross sectional. Only four studies reported data on women with no prior history of CAD. Most of these studies (n = 10) assessed the presence of CAD using questionnaires or medical records. Two studies used CT chest, three studies used CCS, five studies used CTCA and 10 used CAG and one used MPS to assess the presence of CAD. Furthermore, of the 31 studies, 19 studies assessed BAC by its presence/absence and 12 studies visually graded the severity of BAC. For studies that graded BAC severity, five used the same four-point scale system, three used the same 12-point scale system with the remaining four studies using scaling systems that were different from one other ([Table 2](#pone.0236598.t002){ref-type="table"}). Out of these, only 9 studies had data available to calculate the OR of the association of mild BAC or moderate to severe BAC and the presence of CAD.

10.1371/journal.pone.0236598.t002

###### Studies that have visually graded BAC severity and examined the association of BAC severity and CAD.

![](pone.0236598.t002){#pone.0236598.t002g}

  Author                                                                                                                                                                                Scale used                                                                                           Scale definition
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Mostafavi \[[@pone.0236598.ref066]\], Hanafi \[[@pone.0236598.ref029]\], Ružičić \[[@pone.0236598.ref048]\], McLenachan\[[@pone.0236598.ref049]\], Soylu \[[@pone.0236598.ref030]\]   4 point scale                                                                                        1: no vascular calcification
  2: few punctate vascular calcifications, no areas of tram track or ring calcifications (mild)                                                                                                                                                                                              
  3: coarse vascular calcifications of definite tram track or ring appearance affecting \<3 vessels (moderate)                                                                                                                                                                               
  4: severe coarse vascular calcifications affecting \>3 vessels (severe)                                                                                                                                                                                                                    
  Pecchi \[[@pone.0236598.ref055]\]                                                                                                                                                     3 scale; uni/bilateral breast                                                                        Mild: only isolated calcified plaques along the course of the vessels
  Moderate: typical parallel track calcifications seen along part of the arterial vessels                                                                                                                                                                                                    
  Severe: entire, 'punched out' calcified vessels                                                                                                                                                                                                                                            
  Oliviera \[[@pone.0236598.ref039]\]                                                                                                                                                   4 point scale                                                                                        Absent: no vascular calcification
  Slight: arteries clearly outlined by calcification with distances greater than 10mm between calcified areas                                                                                                                                                                                
  Moderate: arteries clearly outlined by calcifications over a considerable proportion of their course                                                                                                                                                                                       
  Severe: arteries extensively affected, seen to have almost continuous columns of calcification with at least two branches also visible                                                                                                                                                     
  Moradi \[[@pone.0236598.ref043]\]                                                                                                                                                     4 point scale                                                                                        Normal: no calcification
  Mild: slightly calcified breast artery                                                                                                                                                                                                                                                     
  Moderate: distinctly calcified breast artery                                                                                                                                                                                                                                               
  Severe: solid calcification of the breast artery                                                                                                                                                                                                                                           
  Topal \[[@pone.0236598.ref038]\]                                                                                                                                                      Uni/bilateral breast; number of blood vessels involved; continuous or discontinuous calcifications   \-
  Margolies \[[@pone.0236598.ref034]\], Fathala (I) \[[@pone.0236598.ref046]\], Fathala (II) \[[@pone.0236598.ref069]\]                                                                 12 point scale (sum of scores for density, length and number of vessels involved                     Density of calcium in most affected segment (0: none; 1: mild with clear visualisation of the lumen and/or only one vessel involved; 2: clouding of lumen and calcification of both tangential walls; 3: severe with no visible lumen)
  Longest length of vessel involvement (0: none; 1: less than one third; 2: one third to two thirds; 3: more than two thirds of vessel length                                                                                                                                                
  Number of vessels (1 to 6)                                                                                                                                                                                                                                                                 
  Mild: score 1 to 4                                                                                                                                                                                                                                                                         
  Moderate: score 5 to 8                                                                                                                                                                                                                                                                     
  Severe: score 9 to 12                                                                                                                                                                                                                                                                      

### BAC and CAD {#sec012}

The pooled OR of the association of BAC and CAD was significant at 2.61 (95% CI 2.12--3.21). Heterogeneity across studies was significant at I^2^ 71% (p\<0.01) ([Fig 2A](#pone.0236598.g002){ref-type="fig"}). When only studies of women with no prior history of CAD were included, the pooled OR of the association of BAC with the presence of CAD was 3.46 (95% CI 1.57--7.61). When studies were analysed based on modality of determining CAD, the OR were 2.16 (95% CI 1.83 to 2.55), 2.14 (95% CI 1.40 to 3.29) and 3.90 (95% CI 2.53 to 6.03) for questionnaires, CAG/MPS and CT, respectively ([Fig 2B](#pone.0236598.g002){ref-type="fig"}). There was no heterogeneity between studies that examined CAD based on questionnaires (I^2^ = 15%; p = 0.30) whereas heterogeneity between studies that examined CAD based on CAG/MPS and questionnaires remained significant at I^2^ = 74% (p\<0.01) and I^2^ = 75% (p\<0.01), respectively.

![Forest plot analysis of breast arterial calcification (BAC) and coronary artery disease (CAD).\
Fig 2A shows the association of BAC and CAD when stratified based on study design. Fig 2B shows the association of BAC and CAD when stratified based on modality of determining CAD. The blue line separates cross sectional and cohort studies. (CT: computed tomography; CAG: coronary angiography.](pone.0236598.g002){#pone.0236598.g002}

When studies were stratified based on method of reporting BAC, the OR were 2.05 (95% CI 1.70--2.47) and 4.04 (95% CI 2.59--6.30) for studies that reported BAC by presence/absence and semi-quantitatively, respectively, with no changes to heterogeneity. A sub-analysis was performed on studies that used the 4-point (n = 4 studies) and 12-point scale system (n = 3 studies). For those that used the 4 point scale system, mild BAC had a pooled OR of 2.04 (95% CI 0.82--5.05) ([Fig 3A](#pone.0236598.g003){ref-type="fig"}) and moderate to severe BAC had a pooled OR of 4.83 (95% CI 1.50--15.53) ([Fig 3B](#pone.0236598.g003){ref-type="fig"}). For those that used the 12 point scale system, the pooled OR was 1.08 (95% CI 0.42--2.75) for mild BAC and 2.95 (95% CI 1.49--5.84) for moderate to severe BAC ([Fig 3C and 3D](#pone.0236598.g003){ref-type="fig"}).

![Forest plot analysis of breast arterial calcification (BAC) and coronary artery disease (CAD) based on BAC severity.\
Fig 3A and 3B shows the association of BAC and CAD using the 4 point scale system. Fig 3C and 3D shows the association of BAC and CAD using the 12 point scale system. Fig 3A and 3C are the forest plot analysis for mild BAC and CAD and Fig 3B and 3D for moderate to severe BAC and CAD.](pone.0236598.g003){#pone.0236598.g003}

Study quality did not have a significant impact on the association of BAC and CAD (Slope = 0.11, 95% CI -0.79 to 1.01, p = 0.82) ([S2 Fig](#pone.0236598.s006){ref-type="supplementary-material"}). Interestingly, the ORs decreased with age, but this was not statistically significant (Slope = -0.03, 95%CI -0.10 to 0.04, p = 0.37) ([S3 Fig](#pone.0236598.s007){ref-type="supplementary-material"}). Sensitivity analysis excluding studies with less than 100 participants did not have a large impact on heterogeneity (I^2^ 75% to 69%). The funnel plot was also asymmetrical (Egger's test p value \< 0.001) ([S4 Fig](#pone.0236598.s008){ref-type="supplementary-material"}).

Studies evaluating BAC and cardiovascular risk factors {#sec013}
------------------------------------------------------

Out of the relevant 59 articles, respectively 42 (n = 32,646), 51 (n = 53,464), 27 (n = 11,652) and 35 (n = 40,002) studies had data available that enabled calculation of ORs for the associations of BAC with hypertension, diabetes mellitus, hypercholesterolemia and smoking. Of these, the number of studies considered good in quality were 19 that reported on hypertension, 21 that reported on diabetes mellitus, 13 that reported on hypercholesterolemia and 20 that reported on smoking.

### BAC and cardiovascular risk factors {#sec014}

Hypertension (OR 1.80; 95% CI 1.47--2.21), diabetes mellitus (OR 2.17; 95% CI 1.82--2.59) and hypercholesterolemia (OR 1.28; 95% CI 1.06--1.55) were significantly associated with the risk of BAC. In contrast, smoking was associated with approximately half the risk for having BAC compared to non-smokers (OR 0.54; 95% CI 0.42--0.70). Marked heterogeneity existed across studies for all analyses ([Fig 4](#pone.0236598.g004){ref-type="fig"}).

![Forest plots of associations of breast arterial calcification with cardiovascular risk factors.\
Odds ratios are shown for studies reporting data on hypertension (Fig 4A), diabetes mellitus (Fig 4B), hypercholesterolemia (Fig 4C) and smoking (Fig 4D). The blue line separates cross sectional and cohort studies.](pone.0236598.g004){#pone.0236598.g004}

When only good quality studies were included in the analysis, the ORs for hypertension increased to 1.99 (95% CI 1.59--2.49) and the ORs for diabetes mellitus and smoking decreased to 1.76 (95% CI 1.46--2.12), and 0.51 (95% CI 0.37--0.69), respectively, whereas the OR for hypercholesterolemia became insignificant (OR 1.31 (95% CI 0.97--1.77). Heterogeneity remained significant.

Discussion {#sec015}
==========

Our quantitative review of the literature showed a positive associations of BAC with risk of CAD and with most of the major cardiovascular risk factors except for smoking. Sub-analysis on BAC severity and the association of CAD revealed that only moderate to severe BAC was associated with CAD. There was marked heterogeneity across studies in all our analyses. The majority of studies were cross-sectional in design and included symptomatic patients which limits interpretation.

BAC and CAD {#sec016}
-----------

We report a positive association between BAC and CAD with a summarised OR of 2.61 (95%CI 2.12--3.21). This is consistent with a previous systematic review that identified only three longitudinal studies and which reported a HR of 1.32 to 1.44 for the association between BAC and risk of CAD \[[@pone.0236598.ref010]\]. However, in these studies, CAD was retrospectively assessed from medical history or records. Two other meta-analysis by Abi Rafeh et al \[[@pone.0236598.ref008]\]and Jiang et al \[[@pone.0236598.ref009]\] that included only studies that assessed CAD with CAG reported that BAC was positively associated with the risk of CAD with an OR of 1.59 (95%CI 1.21--2.09) and 3.86 (95%CI 3.24--4.59), respectively. However, the populations studied were highly selected because CAG is an invasive investigation that is almost exclusively performed on patients with symptoms thought to be due to CAD. Therefore, conclusions cannot be drawn on the usefulness of BAC for screening which, by definition, concerns asymptomatic populations without prior cardiovascular events or cardiovascular symptoms. Furthermore, CAG underestimates the prevalence of CAD because luminal narrowing may not be seen in the presence of arterial remodelling even if the atherosclerotic plaque burden is very high. We attempted to address the limitations of prior meta-analyses by including all studies, irrespective of method of assessment of CAD, resulting in a much higher number of studies The analysis were further stratified by method of assessment of CAD.

When we stratified our analysis based on modality of determining CAD, the association of BAC and CAD identified by CT was the strongest among the three modality groups (OR = 3.90). Assessment of CAD by questionnaires are well recognised to be open to recall and other biases, while CAG can only detect luminal stenosis and may miss the presence of quiescent CAD. Of all the methods used to define CAD in published studies, CT is the most accurate method of detecting the presence of any CAD. These data suggest that BAC could potentially be used to screen for CAD. However, our review identified a major limitation in that most of the studies did not exclude women with prior cardiovascular events, which limits inferences on using BAC for screening purposes. We identified only four studies that included women without CAD (total n = 875). All showed a positive association between BAC and CAD with a pooled OR of 3.46 (95% CI 1.57--7.61). The funnel plot was also asymmetrical suggesting the potential presence of publication bias. Therefore, there is insufficient data to determine whether BAC may be used as a marker for undeclared CAD. Larger prospective studies involving women with no prior history of CAD at baseline are required to determine whether incidental BAC reliably detects quiescent CAD.

There was significant heterogeneity across all the studies in our analysis. When our analysis was stratified based on method of determining CAD, heterogeneity remained significant for studies that assessed CAD by CAG, CT or MPS but not questionnaires. This was in contrast to a previous systematic review that only included studies that looked at CAD assessed by CAG \[[@pone.0236598.ref009]\]. We assessed whether study quality contributed to heterogeneity by performing a meta-regression analysis, but found that it did not. A sensitivity analysis, excluding small studies with participant numbers of less than 100 also did not significantly alter the effects of heterogeneity. We also excluded age as a significant confounder or contributor to heterogeneity which reinforces the suggestion that BAC may be independently associated with CAD. We were unable to control for variations in other characteristics between these studies, such as the different methods of quantifying outcomes that may have contributed to the heterogeneity found across all the studies. Yet, the heterogeneity may also indicate that the overall association between BAC and the presence of CAD is widely generalizable \[[@pone.0236598.ref072]\].

We also found no changes in the association of BAC and CAD and heterogeneity regardless of how BAC was assessed (presence/absence: OR 2.05 (95% CI 1.70--2.47); semi-quantified: OR 4.04 (95% CI 2.59--6.30)). The higher ORs seen in the semi-quantitative method are most likely explained by population differences. Alternatively, it may suggest that semi-quantitative methods are more sensitive in detecting subtle forms of BAC but a head-to-head comparison is required to confirm this. Interestingly, we also observed a significant association between moderate to severe BAC and CAD (OR 4.83 (95% CI 1.50--15.53) and OR 2.95 (95% CI 1.49--5.84) for 4 point scale and 12 point scale, respectively) but not with mild BAC (OR 2.05 (95% CI 0.82--5.05) and OR 1.08 (95% CI 0.42--2.75) for 4 point scale and 12 point scale, respectively). This lack of association between mild BAC and CAD could be explained by the lack of power in these studies to detect a possible association but overall, suggest that there may be an important association between BAC severity and CAD. Additional work using a grading system in longitudinal studies are required. However, there is currently no consensus on a method of assessing BAC. We are unable to comment on which method of assessing BAC is superior over the other as this requires a dedicated study. Furthermore, these methods are semi-quantitative and may be more subjective. A fully quantitative method of assessing BAC may be more objective.

BAC and cardiovascular risk factors {#sec017}
-----------------------------------

We report ORs describing the risk of BAC associated with diabetes mellitus and hypertension of 2.17 (95%CI 1.82--2.59) and 1.80 (95%CI 1.47--2.21), respectively. We also initially found that BAC was associated with the presence of hypercholesterolemia, which is a risk factor for intimal arterial calcification or atherosclerosis \[[@pone.0236598.ref073]\], with an OR of 1.28 (95%CI 1.06--1.55) but this became insignificant when only good studies were included with an OR of 1.31 (95%CI 0.97--1.77). A previous systematic review \[[@pone.0236598.ref010]\] reported only an association between BAC and diabetes mellitus but included far fewer studies and patients and consequently may have lacked the statistical power to identify the association between BAC and hypertension. As BAC is a form of medial arterial calcification \[[@pone.0236598.ref005]\], our findings are consistent with well-known associations of medial arterial calcification for diabetes mellitus \[[@pone.0236598.ref073]\]. The association of BAC and hypertension is interesting as hypertension can promote atherosclerosis and calcification within the tunica media which leads to arterial wall stiffening which in turn could contribute to the development of hypertension \[[@pone.0236598.ref074]\], causing a vicious cycle between hypertension and vascular calcification.

Smoking was found to be inversely associated with the risk of BAC in our study with an OR of 0.54 (95%CI 0.42--0.70). This was similarly observed in a previous systematic review \[[@pone.0236598.ref010]\]. Yet, it is recognised that coronary artery calcification risk is increased with smoking \[[@pone.0236598.ref075]\]. The reasons for this apparent paradox are not known. Potential selective survival of smokers without BAC may in part account for this but another explanation could be that smoking may be a marker of an unidentified confounder. Several studies have attempted to control for smoking status through logistic regression and still reported a positive association between BAC and CAD \[[@pone.0236598.ref032],[@pone.0236598.ref034],[@pone.0236598.ref062],[@pone.0236598.ref066]\]. However, no published studies have stratified their findings between BAC and CAD based on smoking status, which may lead to a different interpretation of the association of BAC and CAD.

Limitations {#sec018}
-----------

A major limitation of this systematic review is that the results are based on published data which have major limitations. For example, most of the studies included in our analysis were cross sectional in design and only a few of the studies specifically targeted women with no prior history of CAD. Therefore, current evidence is insufficient to determine if the measurement of BAC could be used as a screening tool for quiescent CAD. At present, there is also no validated tool to grade the quality of cross sectional studies. We have attempted to overcome this by modifying a standardised method used to appraise cohort and case control studies and which has been used in previous systematic reviews \[[@pone.0236598.ref076]\], but this approach requires validation. We also demonstrated the possibility of publication bias in our study using a forest plot, however, the marked heterogeneity across all the studies could also have accounted for the asymmetry observed on our funnel plot analysis. Another limitation of this systematic review was that bias may be introduced as only one reviewer was primarily involved in selecting, assessing and extracting data from the studies included in this analysis. However, there were secondary reviewers who were available if there were any concerns regarding any of the study included. As our primary outcome included all studies regardless of quality, it is also unlikely that our conclusions would have changed. Finally, we analysed only studies where published data were available.

Conclusion {#sec019}
==========

BAC is associated with CAD and hypertension and diabetes mellitus, but is inversely associated with smoking. However, as most of these studies were cross sectional and included symptomatic women, it remains unclear whether the measurement of BAC could be used as a screening tool for CAD in asymptomatic women who undergo mammography. There may also be an important association between BAC severity and CAD. A consensus on the optimum approach to grade or quantitate BAC is required. Future studies should exclude subjects with known CAD or prior cardiovascular events and ideally use a widely accepted grading system for BAC and be prospective to also enable assessment of the predictive value of BAC and its severity for cardiovascular events.

Supporting information {#sec020}
======================

###### Search strategy used in MEDLINE.

\* Asterisk used to capture multiple word endings (e.g. calcifying, calcification).

(DOCX)

###### 

Click here for additional data file.

###### Critical appraisal of cohort studies included in the meta-analysis.

1: representativeness of cohort (a---truly representative of the community; b---somewhat representative of the community; c---selected group; d---no description), 2: selection of non-exposed cohort (a---drawn from the same community as the exposed cohort; b---drawn from a different source; c---no description), 3: ascertainment of exposure (a---secure record or independent blind assessment; b---single blinded assessment; c---unblinded assessment; d---no description), 4: demonstration that outcome of interest was not present at the start of study (a---yes; b---no), 5: comparability/controlling for confounders (a---study controls for age; b---study controls for any additional factor), 6: assessment of outcome (a---independent blind assessment; b---record linkage; c---self report; d---no description), 7: duration of follow up (a---yes; b---no), 8: adequacy of follow up (a---complete follow up; b---subjects lost to follow up unlikely to introduce bias where \>80% were followed up or description was provided of those lost; c---follow up rate \<80% and no description of those lost; d---no statement), \*: stars given for each question; x: answer marked for each question, +: good, ±: moderate.

(DOCX)

###### 

Click here for additional data file.

###### Critical appraisal of case control studies included in the meta-analysis.

1: case definition (a---yes with independent validation; b---yes with record linkage, self report, non-independent validation; c---no description), 2: representativeness of cases (a---consecutive or obviously representative series of cases; b---potential selection bias or not stated), 3: selection of control (a---community controls; b---hospital controls; c---no description), 4: definition of control (a---no history of disease/endpoint; b---no description), 5: comparability/adjusting for confounders (a---controls for age; b---controls for other additional factors), 6: ascertainment of exposure (a---secure record or two blinded investigators; b---structured interview where blinded to case/control status or one blinded investigator; c---not blinded; d---written self report or medical record only; e---no description), 7: same method of ascertainment of exposure for cases and controls (a---yes; b---no), 8: non response rates (a---same rate for both groups; b---non respondents described; c---rate different and no designation), \*: stars given for each question; x: answer marked for each question; +: good, ±: moderate.

(DOCX)

###### 

Click here for additional data file.

###### Critical appraisal of cross sectional studies included in the meta-analysis.

1: representativeness of the sample (a---truly representative of the average target population; b---somewhat representative of the average target population; c---selected group of participants; d---no description); 2: sample size (a---justified and satisfactory including sample size calculation; b---not justified or no information), 3: Ascertainment of risk factor (a---secured record/clinical registry and validated measurement tool used; b---structured questionnaire and validated measurement tool; c---self report; d---no description), 4: non-respondents/missing comparable data (a---the characteristics between BAC+/- are comparable and response rate is \>50%; b---the characteristics between BAC+/- is not sufficiently comparable and the response rate is \<50%; c---no information provided), 5: comparability/control for confounders (a---data/results adjusted for age; b---data/results adjusted for any additional factors), 6: assessment of BAC (a---independent blinded assessment of BAC; b---single blinded assessment of BAC; c---unblinded assessment of BAC/no description, 7: statistical methods (a---statistical test used to analyse the data clearly described, appropriate and measures of association presented include confidence intervals and p values; b---statistical test not appropriate, not described or incomplete), \*: stars given for each question; x: answer marked for each question, +: good, ±: moderate.

(DOCX)

###### 

Click here for additional data file.

###### Newcastle Ottawa Scale used to assess the quality of cross-sectional studies.

(TIF)

###### 

Click here for additional data file.

###### Meta-regression plot of the odds of breast arterial calcification (BAC) being associated with coronary artery disease (CAD) against the quality score of the study.

Each bubble represents one single study and its size corresponds to the study sample size. The odds of BAC being associated with CAD had a slight upward trend with quality of the study (slope = 0.059; p = 0.889).

(TIF)

###### 

Click here for additional data file.

###### Meta-regression plot of the odds of breast arterial calcification (BAC) being associated with coronary artery disease (CAD) against standardised mean age.

Standardised mean age was calculated as mean age of all study included in analysis---mean age of individual study. Each bubble represents one single study and its size corresponds to the study sample size. The odds of BAC being associated with CAD had a downward trend with age (slope = -0.032, p = 0.323).

(TIF)

###### 

Click here for additional data file.

###### Funnel plot of studies that examined the association between breast arterial calcification (BAC) and coronary artery disease (CAD).

Each dot represents a study. The solid vertical line represents the summary estimate of the log odds ratio of BAC and CAD and the triangle is fixed on the summary estimate and extends 1.96 standard errors either side. The distribution of studies are asymmetrical and more than 5% of the studies are outside the white triangle which indicates potential publication bias but could also result from heterogeneity.

(TIF)

###### 

Click here for additional data file.

###### Forest plot analysis of breast arterial calcification (BAC) and coronary artery disease (CAD) based on study design.

S5 Fig A shows the association of BAC and CAD in cross-sectional studies. S5 Fig B shows the association of BAC and CAD in cohort studies.

(TIF)

###### 

Click here for additional data file.

###### PRISMA 2007 checklist.

(DOC)

###### 

Click here for additional data file.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In this paper, the authors aim to assess the associations between breast arterial calcification (BAC) and the risk of cardiovascular disease and its risk factors (hypertension, hypercholesterolemia, diabetes mellitus and smoking). A systematic literature search updated until February 2020 was conducted and a meta-analysis was finally performed on 59 good-quality studies according to modified Newcastle Ottawa Scale (NOS) scale. Odds ratios and 95% confidence intervals were extracted that examined risk factors for BAC or associations of BAC with cardiovascular disease. Age was taken into account as a confounding variable and meta-regression analysis was performed. Heterogeneity among studies was verified. No publication bias was encountered. Conclusions state that BAC is associated with CAD and hypertension and diabetes mellitus, but is inversely associated with smoking.

It remains unclear whether the measurement of BAC could be clinically translated and future studies are needed.

Strengths

− A good methodology was applied in systematic review and meta-analysis.

− No publications bias occurred.

− Association of BAC with cardiovascular risk factors and disease was confirmed

− Sections are consistent throughout the manuscript and adequately written and organized

Weaknesses

− The current meta-analysis does not add to the body of evidence concerning BAC and cardiovascular risk.

− Search strategy should be explicated in Methods.

− Even if this review was conducted in concordance with the PRISMA statement, ideally two researchers should independently perform the data extraction.

− As description of method of quantifying BAC has been extracted, it would have been interesting to present results about that, that currently represent the crucial gap in clinical translation of BAC for preventive cardiology in women. No published systematic data are on this.

− What's the BAC prevalence estimate?

− Table 1 report only 50 studies. Are 9 studies missing?

− What's the EMBED database? Do you mean EMBASE? Otherwise please give source.

Conclusion

− The literature search and meta-analysis are well conducted

− The paper is well written but does not add in evidence.

− Discussion could be enriched

Reviewer \#2: This study is a systematic review and meta-analysis for studies of BAC as risk factor of cardiovascular disease and its risk factors. The results show that BAC is indeed associated with CAD, diabetes and hypertension

Several comments can be made:

1\. Introduction: no mention is made of the fact that BAC concerns a specific form of calcification namely medial calcification and that this form of calcification may also have different pathways to lead to CVD. This should be indicated in the paper.

2\. Introduction: an earlier systematic review and meta-analysis was performed on this topic (Hendriks EJ, atherosclerosis, 2015). This study should be referenced and the authors should indicate what this additional meta-analysis will add.

3\. Methods; only 1 reviewer performed study selection, data extraction and quality assessment. This is a limitation of the study.

4\. Methods: can the authors provide a little more detail on how quality was assessed for study population, control for confounding and the outcome. The number of points is indicated but not how this is specifically applied to these studies and which items under these headings were scored. This information could be provided in a supplement.

5\. Methods; CAD is very heterogenous endpoint. Can the authors perform subgroup analyses for different outcomes such as coronary heart disease and stroke or otherwise specify wheter only events or also CAD mortality was investigated and perform subgroup analyses for this.

6\. Results: can the authors also do subgroup analysis separating cross-sectional from prospective studies?

7\. Discussion: the authors indicate that only 4 studies excluded those with previous CVD. Is it also possible to provide a pooled estimate for these 4 studies?

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Joline W Beulens

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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19 Jun 2020

Dear Reviewers,

Re: PONE-D-20-11782 - Is breast arterial calcification associated with coronary artery disease? - A systematic review and meta-analysis

We would like to thank you for your helpful comments for improving our paper. We have addressed each as follows:

• Abstract:

o Updated with additional data

• Introduction:

o Reference made about BAC being a form of medial arterial calcification

o Emphasised that our primary aim will add to current literature by briefly commenting on prior systematic reviews and meta-analyses

� Updated with more studies added

� Our review will look at CAD across multiple modalities

• Methods:

o Provided further details on our search strategy

o Defined CAD in more detail

o Stratified studies based on whether BAC was quantified or not

o Added a sub-analysis of studies that quantified BAC and its association with the presence of CAD

• Results:

o Provided the 9 missing data on Table 1 that was left out during the initial editing process -- does not affect results and conclusions

o Studies evaluating BAC and CAD and BAC and CAD sections

� Number of studies have changed as we have decided to focus primarily on CAD and have excluded studies that had combination endpoints (e.g. CAD and stroke) -- this has slightly increased the odds of BAC and CAD but has not changed our conclusions

� Provided results regarding studies that have quantified BAC

• A new table has been included in the manuscript detailing the different methods used by studies to quantify BAC (Table 2)

• Association of BAC and CAD not affected by method of scoring BAC

• Sub-analysis showed moderate to severe BAC associated with CAD but not mild BAC using the two most commonly used method of assessing BAC severity (4 point and 12 point scale system) (Fig 3)

� Stated the ORs of BAC and CAD in women asymptomatic of CAD.

o BAC and cardiovascular risk factors section

� Fig 4 (previously Fig 3) has been modified to emphasise that data taken from baseline characteristics of cohort studies are cross-sectional data.

� Small changes in numbers from the Schnatz paper has led to minor alterations in the pooled ORs. This has not affected overall results and conclusion (used prospective data rather than baseline data)

• Discussion:

o Made changes relevant to results

o New paragraph added to discuss results on the severity of BAC and the association of CAD

• Limitations:

o Added a statement regarding the use of primarily one researcher in data extraction and analysis as a limiting factor

• Conclusion:

o Added comment that there may be an important association between BAC severity and CAD

• Supplementary material:

o Table S2-S4 has been modified to incorporate further details on how study quality was assessed

• Other analysis carried out but not included in manuscript:

o Stratified analysis of cross sectional and cohort studies

The following are our responses to each reviewer in greater detail:

REVIEWER ONE

1\. The current meta-analysis does not add to the body of evidence concerning BAC and cardiovascular risk.

We thank the reviewer for this comment and have modified the manuscript to clearly state the additional information provided by our analysis regarding BAC and CAD. Three prior papers aimed to summarise the association between BAC and CVD. Abi Rafeh et al (2012) included only five studies and reported a positive OR of 1.59 (95%CI 1.21-2.09). Jiang et al included ten studies and summarised the odds of the association of BAC and CAD on CAG as 3.86 (95%CI 3.25-4.59). The most recent systematic review by Hendriks et al did not perform a meta-analysis but reported the range of adjusted hazard ratios as a range based on three identified studies (HR 1.32 (95%CI 1.08-1.60) to HR 1.44 (95%CI 1.02-2.05). All these prior papers included only the use of CAG and excluded studies that assessed CAD using CT-scans or questionnaires. It is recognised that CAG, being a luminogram, underestimates the presence of CAD in the presence of remodelling, which is common in early and even advanced atherosclerosis. CT-scans, on the other hand, can detect coronary plaque even when the coronary lumen is widely patent. We will be the first to systematically review studies that examined CAD from questionnaires, CAG, MPS and CTs. Our systematic review will also be the first to assess whether the association of BAC and CAD is sensitive to 1) the method used to assess CAD or 2) whether or not only patients are truly asymptomatic or have symptoms suggestive of CAD are included and 3) the method of reporting or grading BAC).

Only one prior study has evaluated the relationship between BAC and CVD risk factors. Hendriks et al looked at the associations of BAC and hypertension (11 studies), diabetes (14 studies), hypercholesterolemia (4 studies) and smoking (20 studies). Only studies of moderate to good quality were included in their analysis and amongst these, a positive association between BAC and diabetes and an inverse association between BAC and smoking was reported. We included studies of all quality and did a sub-analysis that included only good quality studies. This has resulted in a higher number of studies (hypertension: 42 studies; diabetes: 51 studies; hypercholesterolemia: 27 studies; smoking: 35 studies) included in our analysis but with multiple publications since then, we also had higher number of good quality studies in our sub-analysis (hypertension: 19 studies; diabetes: 21; hypercholesterolemia: 13; smoking: 20). By doing so, our results are in keeping with those by Hendriks et al, but we provided new evidence on the relationship between BAC and hypertension. This is probably due to the higher number of studies we have included in our analysis.

2\. Search strategy should be explicated in Methods.

Thank you for your comment on our search strategy. We have expanded the information of our search strategy in our methodology under data sources and searches. To emphasise that our primary aim is to look at CAD specifically, we have defined CAD clearer in the study selection section of the methods.

3\. Even if this review was conducted in concordance with the PRISMA statement, ideally two researchers should independently perform the data extraction.

We have acknowledged this in our study limitations.

4\. As description of method of quantifying BAC has been extracted, it would have been interesting to present results about that, that currently represent the crucial gap in clinical translation of BAC for preventive cardiology in women. No published systematic data are on this.

Thank you for this interesting point. We agree that this will be interesting and novel data and have performed a sensitivity analysis by stratifying studies that have graded BAC and those that have not. We found that there were no changes to the association nor heterogeneity. An apparently higher odds was observed in studies that graded the severity of BAC vs reporting only the presence or absence of BAC ((OR 4.04 (95%CI 2.59-6.30) vs OR 2.05 (95%CI 1.70-2.47) and this is likely due to population differences but could also indicate that semi-quantitative methods are more sensitive at detecting subtle forms of BAC.

We identified 12 studies that have visually graded the severity of BAC and these are summarised in a table (Table 2). Of these, five studies used the same 4 point scale system and 3 studies used the same 12 point scale system. The other 4 studies have used different grading systems that could not be grouped together. There were only 9 studies with extractable data (4 studies with the 4 point scale system; 3 studies with the 12 point scale system; 2 studies that could not be grouped). We chose to perform two sub-analyses on BAC severity and the association of CAD using studies from 4- and 12-point scale system. These were stratified to mild and moderate/severe BAC. We chose to group moderate and severe BAC together due to the small numbers. Interestingly, we found that a positive association between moderate to severe BAC (OR 4.83 (95%CI 1.50-15.54) and OR 2.95 (95%CI 1.49-5.84), respectively) but not mild BAC (OR 2.04 (95%CI 0.82-5.05) and OR 1.08 (95%CI 0.42-2.75), respectively). We believe that this suggest a possible association between BAC severity and CAD. This advocates for the need of a consensus in a method of assessing BAC severity and also larger prospective studies which incorporate grading of BAC. Furthermore, all studies to date have used a semi-quantitative method that is subjected to biasness and we have suggested that a direct quantitative method may be warranted. We have included this analysis in the results and added a discussion on the implications.

5\. What's the BAC prevalence estimate?

We have provided the prevalence of BAC in Table 1 to allow appreciation of BAC prevalence amongst different population groups. In the general population, BAC prevalence varied from 3.0 to 63.7% with notably higher BAC prevalence in those who were symptomatic for CAD. In post-menopausal women, BAC prevalence ranged from 8.5 to 59.5%. BAC prevalence seemed to be higher in women with diabetes and chronic kidney disease at 36.5 to 45.1% and 14.5 to 54.8%, respectively.

6\. Table 1 report only 50 studies. Are 9 studies missing?

Thank you for pointing out this error. Whilst all studies were included in the generation of the results, there were 9 studies that were accidentally removed from Table 1 during the editing process. This has been corrected. Importantly, the data from these studies were included in our initial analysis so that the relevant results and conclusions have not changed.

7\. What's the EMBED database? Do you mean EMBASE? Otherwise please give source.

Yes, we meant EMBASE and this has been corrected in the manuscript.

REVIEWER 2

1\. Introduction: no mention is made of the fact that BAC concerns a specific form of calcification namely medial calcification and that this form of calcification may also have different pathways to lead to CVD. This should be indicated in the paper.

We recognise the importance of highlighting that BAC is a form of medial arterial calcification and could explain why it is not routinely reported. We have now discussed this in our introduction.

2\. Introduction: an earlier systematic review and meta-analysis was performed on this topic (Hendriks EJ, atherosclerosis, 2015). This study should be referenced and the authors should indicate what this additional meta-analysis will add.

Thank you for your comment. We believe that this will further highlight the importance of doing an updated systematic review on the association of BAC and CAD as the prior systematic review had only looked at three longitudinal studies for the association of BAC and cardiovascular events. One of them looked at cardiovascular mortality and the other two had information on the association of BAC and CAD. Our systematic review has specifically examined the association between BAC and CAD and is the first systematic review to include all studies (case controls, cross sectional, cohort studies) in our analysis. This has added an additional 29 studies to the previous systematic review (total 31 studies that examined BAC and specifically CAD). Furthermore we also include studies that have assessed the presence of CAD using CT-scans or questionnaires, enabling a further sensitivity analysis with discussion of the strengths and limitations of using these different methodologies.

3\. Methods; only 1 reviewer performed study selection, data extraction and quality assessment. This is a limitation of the study.

We have acknowledged this in our study limitations.

4\. Methods: can the authors provide a little more detail on how quality was assessed for study population, control for confounding and the outcome. The number of points is indicated but not how this is specifically applied to these studies and which items under these headings were scored. This information could be provided in a supplement.

The tables regarding the scoring of each study has been modified to include further details on how quality was assessed (see S2-S4 Tables).

5\. Methods; CAD is very heterogenous endpoint. Can the authors perform subgroup analyses for different outcomes such as coronary heart disease and stroke or otherwise specify whether only events or also CAD mortality was investigated and perform subgroup analyses for this.

Thank you for your constructive feedback. We agree that cardiovascular disease is a very heterogenous endpoint and may include CAD and stroke. As such, we have decided to examine the association of BAC and specifically CAD. To facilitate this, the definition of CAD has now been included where CAD is defined by medical history/records (history of myocardial infarction or angina, positive stress test or abnormal CAG, coronary revascularisation), presence of CAD on CAG, presence of perfusion defect on MPS and presence of coronary artery calcium on CTCA, CT chest and CCS. As a result, we have re-reviewed all studies that were included in our initial analysis and found that there were three studies (Kelly, Soran, Ferreira) that combined multiple endpoints as cardiovascular disease (e.g. stroke, thrombosis, transient ischaemic attacks). As it is not possible to extract data specifically on CAD from these studies, we have now excluded them. We also had to change the data entered from the Schnatz paper as there were multiple endpoints for CAD which included abnormal CAG and history of myocardial infarction. The initial analysis extracted data from history of myocardial infarction but we feel that abnormal coronary CAG may be a better reflection of the presence of CAD. We have made a point of this in our methods (line 207-209). We have also switched the Kemmeren paper with the van Noord paper as the latter has listed the specific number of participants with a history of myocardial infarction. Both these papers were from the same cohort but the Kemmeren paper had combined the endpoints of history of myocardial infarction, stroke/TIA and thrombosis. As such, the number of cohort studies have reduced from six to three. Therefore, the final number of studies included in our analysis is now 31. Despite these changes, our conclusions have not changed and the OR for the association of BAC and CAD has now increased from 2.56 (95%CI 2.11-3.12) to 2.61 (95%CI 2.12-3.21). All sub-analysis that were performed in the initial analysis were also repeated with the same conclusions.

With regards to CAD mortality, there is only one study that have looked at the association of BAC and CAD mortality -- Kemmeren et al at where an adjusted HR of 1.44 (95%CI 1.02-2.05) was observed. We have not included this study in our analysis as we have now chosen to specifically look at CAD. This is reflected by the changes on Table 1 which now excludes the Kemmeren paper and included the van Noord paper.

6\. Results: can the authors also do subgroup analysis separating cross-sectional from prospective studies?

A subgroup analysis separating cross-sectional from prospective studies had no impact on the odds as well as heterogeneity. The pooled ORs were 2.68 (95%CI 2.11-3.40) and 2.53 (95%CI 1.43-4.45) for cross sectional and prospective studies, respectively. We have included these results in the supplementary materials.

7\. Discussion: the authors indicate that only 4 studies excluded those with previous CVD. Is it also possible to provide a pooled estimate for these 4 studies?

The pooled estimate for these 4 studies remained positive at a higher odds of 3.46 (95%CI 1.57-7.61) with significant heterogeneity at I2=84% (p\<0.01). We will report this in our results (line 329-331) and discussion (line 490).

We would like to thank both the Reviewers and Editors for your constructive comments, which we feel has improved our manuscript.

With many thanks,

Dr Sing Ching Lee
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